Psilocybin
Optimi Health obtains license to produce natural health products
Natural products include probiotics, herbal remedies, vitamins and minerals, homeopathic medicines, traditional medicines among others
The post Optimi…
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) has expanded its repertoire of compounds besides psychedelics after receiving permission to produce natural health products
The company announced Tuesday it has received a Natural Health Product Site License, allowing the company to manufacture, package and label natural health products at its Princeton, B.C. production facility. Natural health products include probiotics, herbal remedies, vitamins and minerals, homeopathic medicines, traditional medicines such as Chinese medicines and other products like amino acids and essential fatty acids.
The license expands the company’s ability to produce psychedelic and natural health products on-site for global distribution.
“This license enables the company to further diversify and leverage the potential of its existing manufacturing, processing and packaging capabilities to streamline fulfilment and reduce costs across its supply chain to support continued growth,” Optimi CEO Bill Ciprick said in a statement.
Optimi Health is focused on supplying large-scale research and development programs through its 10,000-square-foot facility compliant with good manufacturing practices.
The company is licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances such as MDMA and natural GMP-grade psilocybin, as well as natural health product formulations.
Read more: Optimi Health enters $1.2M psilocybin distribution agreement
Read more: Optimi Health secures MDMA and psilocybin distribution agreement in Australia
Ciprick said the expanded licence allows Optimi to encapsulate products on site, in addition to manufacturing, packaging and labelling natural health products.
Optimi’s operations are focused on developing and distributing mushroom-derived natural health products, as well as compounds for medical research.
The announcement signals Optimi’s intention to continue expanding and diversifying its operations, Ciprick said. Further licensing will be required for the company to produce and distribute natural health products for commercial retail sales.
Last week, the company announced it secured a $1.2 million psilocybin supply agreement with a private client that will be using the company’s mushrooms for clinical research purposes.
Optimi stock went up by 4.26 per cent on Wednesday to $0.24 on the Canadian Securities Exchange.
The post Optimi Health obtains license to produce natural health products appeared first on Mugglehead Magazine.
psilocybin mdma psychedelic psychedelics mushroom cse optimi health optimi health canada research-
Psychedelics1 week ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics1 week ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Law & Regulation1 week ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psilocybin1 week ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment